- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- US Capitol Capsule: Once 'market failure,' orphan drugs ripe for investing
- US Capitol Capsule: Consumer Rx loans, paying for big initiatives: BIO 2014 sizzlers
- Double Irish off: impact on biopharma companies
COMMENT Other Informa Comment
- Profile: Janssen R&D boss on the next big thing in medicine & 'ice bucket' funding
- Profile: The ABPI's reimbursement director on Pfizer, his TicTac salary, and paper mache